Friday, May 14, 2021

Protalix BioTherapeutics Inc. (PLX) stock is falling in premarket, Why is this happening?

Protalix BioTherapeutics, Inc. (NYSE American: PLX) a biopharmaceutical company focused on manufacturing recombinant therapeutic proteins with clinically improved profiles, confirmed receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning the Biologics License Application (BLA) attempting to fast-track approval for use of pegunigalsidase alfa (PRX‑102) for the potential treatment of adults effected with Fabry disease. PLX stock declined immensely adjacent to the news.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



At last check-in premarket trading, shares of Protalix BioTherapeutics Inc. (PLX) were down -43.57% at $3.79. Protalix BioTherapeutics Inc.’s stock subtracted -4.74% to finish last trading session at $5.83. Shares of the company fluctuated between $5.51 and $6.19 throughout the day. For the last six months, the stock has gained a total of 65.16%.

ProtalixBioTherapeutics Regulatory Approach


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


The PRX-102 BLA was initially given priority review by FDA due to its potential to provide immense advancement in treatment of serious diseases. It was submitted under the accelerated approval to fast-track approval and be used in serious conditions with no alternative medicines.

The Biological license application submission for PRX‑102 was inclusive of detailed preclinical, clinical, and manufacturing data compiled from the concluded Phase I and II clinical trial of PRX‑102. The data also included the extension study after the Phase I/II clinical trial, and interim clinical data from the Phase III BRIDGE switch-over study and safety.

“While disappointing, we remain confident in the strength of our data and in the depth of our program,” said Dror Bashan, Protalix’s President, and Chief Executive Officer.”Protalix is currently studying the complete response letter from FDA to provide adequate date for regulatory advancement and understand the actions required to further obtain approval of PRX 102.

Fabry disease is an X-linked genetic disease caused due to decreased activity of the lysosomal α‑Galactosidase‑A enzyme, as a result abnormal deposits of a fatty substance in the blood vessel walls is present. Symptoms include periods of pain, gastrointestinal (GI) symptoms, tiredness, random sweating and can climb up to serious problems such as cardiovascular, renal, and cerebrovascular events.

Protalix has partnered with ChiesiFarmaceuticifor manufacturing and development of pegunigalsidase alfa, and with SarcoMed USA, Inc. for the global commercialization of PRX-110 to treat any human respiratory disease or condition including, sarcoidosis and pulmonary fibrosis.

Conclusion:

Disapproval by FDA has set back research and lowered investor expectation with ProtalixBioTherapeutics stock plummeting immensely. However strategic collaborations combined with adequate actions to fulfil regulatory requirements can be beneficial for the company in the long run.

Latest news

What is behind the fall of Torchlight Energy Resources Inc. (NASDAQ: TRCH) stock?

Torchlight Energy Resources, Inc. (NASDAQ: TRCH), a growth oil and gas exploration company specializing in the acquisition and development of highly profitable domestic oil...

Eros STX Global Corporation (ESGC) stock is declining: Here is the reason why?

Eros STX Global Corporation (NYSE ESGC) a global multinational media company that acquires, produces, and distributes films, television shows, and digital content issued its...

Yum China Holdings Inc. (YUMC): The Most Important Numbers You Should Know

Yum China Holdings Inc. (YUMC), which operates Taco Bell Restaurants, KFC Restaurants, and Pizza Hut Restaurants in China, has published its first-quarter report for...

Why shares of Akerna Corp. (KERN) stock are up today?

Akerna (KERN), a cannabis technology company focusing to connect data points in the global cannabis supply chain and developer of the cannabis industry's first...

Related news

What is behind the fall of Torchlight Energy Resources Inc. (NASDAQ: TRCH) stock?

Torchlight Energy Resources, Inc. (NASDAQ: TRCH), a growth oil and gas exploration company specializing in the acquisition and development of highly profitable domestic oil...

Eros STX Global Corporation (ESGC) stock is declining: Here is the reason why?

Eros STX Global Corporation (NYSE ESGC) a global multinational media company that acquires, produces, and distributes films, television shows, and digital content issued its...

Yum China Holdings Inc. (YUMC): The Most Important Numbers You Should Know

Yum China Holdings Inc. (YUMC), which operates Taco Bell Restaurants, KFC Restaurants, and Pizza Hut Restaurants in China, has published its first-quarter report for...

Why shares of Akerna Corp. (KERN) stock are up today?

Akerna (KERN), a cannabis technology company focusing to connect data points in the global cannabis supply chain and developer of the cannabis industry's first...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.